`
`Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study | Precision Medicine Online
`
`Personalis MRD Assays to Support UK's
`TRACERx ctDNA Monitoring Study
`
`Apr 05, 2023 | staff reporter
`
`NEW YORK – Cancer Research UK, University College London, and the Francis Crick Institute said
`Wednesday that they have adopted Personalis' NeXT Personal, a personalized residual disease detection
`platform, in their TRACERx study.
`
`Already ongoing for several years, TRACERx has been a notable venue for discovery and validation of
`post-surgery liquid biopsy cancer monitoring techniques, tracking early-stage non-small cell lung cancer
`patients after curative-intent surgery.
`
`Moving forward, the UK institutions said they will be using Personalis' assay platform as they begin taking
`"practical steps to make precision medicine for lung cancer patients a reality."
`
`Investigators will create personalized assays, informed by upfront whole-genome sequencing of tumor
`tissue, to identify and track minimal residual disease, identify relapse earlier than possible with current
`imaging technologies, and study disease evolution.
`
`"Thanks to the TRACERx study, we've already seen the importance of ctDNA in predicting cancer
`recurrence in an initial cohort of patients," the study's principal investigator Charles Swanton, who is
`affiliated with all three of the institutions, said in a statement. "Personalis' highly sensitive [test] will allow us
`to achieve a rich understanding of the complex tumor ecosystem, including by tracking clinically relevant
`ctDNA variants at recurrence, and ultimately allowing us to make more informed decisions about patient
`care," he added.
`
`Filed Under
`
`Molecular Diagnostics
`
`Precision Oncology
`
`Liquid Biopsy
`
`Europe
`
`North America
`
`CRUK
`
`Francis Crick Institute
`
`Personalis
`
`non-small cell lung cancer
`
`circulating tumor DNA
`
`Minimal Residual Disease (MRD) Testing
`
`University College London
`
`Privacy Policy. Terms & Conditions. Copyright © 2023 GenomeWeb, a business unit of Crain
`Communications. All Rights Reserved.
`
`https://www.precisionmedicineonline.com/molecular-diagnostics/personalis-mrd-assays-support-uks-tracerx-ctdna-monitoring-study
`
`1/1
`
`Personalis EX2153
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
